key: cord-0806655-669zpo43
authors: Corstjens, Paul L. A. M.; Abrams, William R.; Malamud, Daniel
title: Saliva and viral infections
date: 2015-12-10
journal: Periodontol 2000
DOI: 10.1111/prd.12112
sha: fe51cf350d973b0d569b5b6f1a1afd65bb17aa9a
doc_id: 806655
cord_uid: 669zpo43

Over the last 10 years there have been only a handful of publications dealing with the oral virome, which is in contrast to the oral microbiome, an area that has seen considerable interest. Here, we survey viral infections in general and then focus on those viruses that are found in and/or are transmitted via the oral cavity; norovirus, rabies, human papillomavirus, Epstein‐Barr virus, herpes simplex viruses, hepatitis C virus, and HIV. Increasingly, viral infections have been diagnosed using an oral sample (e.g. saliva mucosal transudate or an oral swab) instead of blood or urine. The results of two studies using a rapid and semi‐quantitative lateral flow assay format demonstrating the correlation of HIV anti‐IgG/sIgA detection with saliva and serum samples are presented. When immediate detection of infection is important, point‐of‐care devices that obtain a non‐invasive sample from the oral cavity can be used to provide a first line diagnosis to assist in determining appropriate counselling and therapeutic path for an increasing number of diseases.

There is no single infectious route used by all viruses. Human viral infection and transmission can occur through multiple paths, such as fecal-oral, ingestion of contaminated food and drinks, sexual contact, exposure to infected blood, exchange of saliva or by aerosols generated by sneezing or coughing. Common examples of viruses isolated from the oral cavity include rotavirus, norovirus, HIV, hepatitis C virus, herpes simplex viruses 1 and 2, Epstein-Barr virus and influenza viruses.

Influenza and the common cold viruses are among the most frequent types of human viral infections. The common cold is generally not life threatening and usually resolves without medical intervention. As it is caused by a group of highly contagious airborne viruses for which no vaccine is available, the best protection is to avoid close proximity to individuals who are infected. By contrast, influenza results in many fatalities, particularly in the elderly and in individuals with suppressed immune systems. Annually modified influenza vaccines available in the western world were initially offered to individuals at risk but are now available to everyone. However, it should be noted that (87) 'The influenza vaccine was only 62% effective among people who did not receive influenza vaccination in the prior year. In comparison, vaccine effectiveness among those who did get influenza vaccination in the previous year was substantially lower.' Occasionally, a new influenza variant may cause a pandemic as a result of zoonosis (i.e. transmission of an animal flu virus to humans) or 'genetic recombination' (more precisely, reassortment of gene segments) of a human virus with a nonhuman form that crosses species. Well-known recent examples of these are swine flu and avian or bird flu, which is sometimes confused with the zoonotic severe acute respiratory syndrome virus (a corona virus). Worldwide policies to reduce or eliminate the risk of epidemics have had some success, and several infectious diseases have been largely eradicated or are under control in the western world as a result of national vaccination programs. The most successful example of a human-driven eradication is that of the smallpox virus following implementation of a worldwide vaccination strategy. This approach succeeded because the smallpox virus (variola) is essentially comprised of a single strain and does not have an animal vector. The approach to measles is another example demonstrating the success of vaccines. Measles is a highly contagious infection of the respiratory system that spreads through aerosol transmission or contact with nasal and oral fluids. Effective vaccines are available and in the USA measles was declared eliminated in 2000. In 2010, at the 63rd World Health Assembly, a global goal was proposed to eliminate the disease with a target of a 95% reduction in mortality by 2015. Unfortunately, there has been a recent measles outbreak in the USA (288 cases), mostly in unvaccinated individuals (www.CDC.gov/measles/).

As a result of new vaccines and vaccination policies, and also improved medical care and development of novel drugs, worldwide infectious disease fatalities have not increased in the past two decades. However, a significant decrease worldwide can be expected only when the equivalent of western world resources become available in resource-poor areas. The global approach to eradicate polio is another example, with currently up to 80% of the world's population living in polio-free regions and a 'collaborative strategic endgame plan' in place to eradicate the last reservoirs of polio (the Global Polio Eradication Initiative). The list of viral infections and viral diseases is extensive and the eradication of one pathogen may provide a niche for another pathogen to become more virulent. Naturally acquired immunity through exposure to the pathogen is likely to provide the best protection against recurring infection.

The presence of viable virus in oral fluid specimens is typically demonstrated by screening for viral nucleic acids. Initially, the viral nucleic acid is isolated from the oral fluid sample directly or after centrifugation performed to concentrate cell-associated virus. This is usually followed by PCR amplification of a virus-specific viral nucleic acid fragment or by using a signal amplification technology. For HIV viral-load analysis, a frequently used commercial assay, based on viral nucleic acid amplification, is the COBAS â Amplicor HIV-1 Monitor Test (Roche Diagnostics, Indianapolis, IN, USA) and an example of a commercial assay based on signal amplification is the VERSANT â HIV-1 RNA Assay (Siemens AG, Munich, Germany).

Viral nucleic acid-based methods are more sensitive and considered less contagious because pathogens in the sample are inactivated during the initial viral nucleic acid isolation protocol. However, amplification-based detection of viral nucleic acid is relatively expensive, requires trained personnel and specific equipment and may not always be proof of an active infection. Ultimately, a cultivation confirmatory test may be needed to obtain a definitive diagnosis. Detection of viral antigens by indirect fluorescent antibody labeling or electron microscopic techniques can be used to detect the presence of intact viral particles. Note that the presence of microscopically intact viral particles in a specific biological fluid/matrix cannot distinguish viable/infectious virus from noninfectious virus.

A list of examples of viable viruses detectable in oral fluid samples is provided in Table 1 . In contrast to serum or plasma, there is no standard protocol for saliva/oral fluid collection and thus saliva may refer to whole-mouth stimulated or unstimulated saliva or to a sample obtained with an oral swab or brush. Filtered or centrifuged saliva can be used to detect free virus, but the virus may be free or cell-bound when using whole saliva or oral swabs. Not all viruses are easily cultivated, and in contrast to bacteria they cannot be directly grown in culture media, but require specific living cells to support their replication. Human papillomavirus, hepatitis C virus, herpes simplex virus, human herpesvirus 8, coronaviruses and the rhinoviruses are examples of viruses known to be difficult to culture. Determining the presence of viable virus in oral fluid samples does not always indicate that the virus can be transmitted orally. In the case of cytomegalovirus, a member of the Herpesviridae family, it is known that transmission occurs via direct contact with body fluids. Although serology suggests a prevalence of cytomegalovirus of up to 80%, blood donors are not routinely tested for active cytomegalovirus infections because the virus in blood is cell associated and leucocyte-depleted red-bloodcell products are considered cytomegalovirus safe. However, the situation in saliva is probably different. The cytomegalovirus transmission route through saliva is similar to that following infection with Epstein-Barr virus, a Herpesviridae member responsible for causing infectious mononucleosis ('kissing disease') and oral hairy leukoplakia.

In contrast, many studies focusing on HIV describe inactivation of the virus by salivary components and indicate that the likelihood of transmitting HIV by saliva is extremely low. A few reports mention the isolation of viable HIV from an oral fluid sample (13, 79) ; further analysis of these 'infective' saliva samples (26) showed that they lacked both specific anti-HIV immunoglobulins and nonspecific antiviral activity. In addition to reports of human viruses, some studies describe the presence of viable plant pathogens in human oral samples; for example, the tobacco mosaic virus was identified in sputum samples from smokers (7, 65) . Although speculated, associations of this plant virus with specific communicable diseases have not been established.

Recent examples demonstrating viral nucleic acid in the oral cavity by amplification of specific viral nucleic acid fragments are shown in Table 2 . Besides the currently widely utilized viral nucleic acid-based detection methods, immunologic-based diagnostics of pathogen-derived antigens are also used to demonstrate active infection. For example, detection of hepatitis B surface antigen is a common test amenable for salivary diagnosis (5) of hepatitis B virus. Other antigen assays demonstrating active viral infections using oral samples have been described for ebola (44) , rabies (72) and HIV (62, 86) . Pathogenderived antigens (e.g. p24 for HIV) are often present at higher levels than the viral genome, and identifying such abundant viral proteins (>1,000 copies per Nucleic acid amplification is compatible with the simultaneous screening or detection of multiple pathogens in a single sample using multiple pairs of DNA primers specific for the targeted microorganisms. The development of fully integrated rapid test devices, capable of analyzing clinical samples for a panel of specific pathogen targets, would be of great value for point-of-care use. Such devices are feasible with the currently available viral nucleic acid-amplification technology; however, cost and sample-preparation issues still need to be addressed (45, 71) . Recent technological advances have allowed analysis by deep sequencing of the human salivary microbiome to create a catalog of all the microorganisms present in saliva and oral mucosa. Analysis of the salivary virome (94) , the virus subset of the salivary microbiome, demonstrated that the majority of oral viruses are bacteriophages. It is postulated that because these phages require bacterial cells for replication they probably play an important role in the microbial diversity and health of the oral cavity and may also influence the susceptibility to human viral infections. Optimization of oral fluid viral nucleic acid-isolation methods, combined with the availabil-ity of high-throughput sequencing and analysis technologies, will provide useful tools to identify known, as well as unknown, viruses (24) .

Although not widely utilized, immunologic detection of active infection has been reported for infections other than HIV. For example, dengue virusspecific IgA in serum and saliva was detected soon after infection in dengue-endemic regions (133) . Moreover, dengue-specific IgM/IgG levels may be used to distinguish between primary and secondary infections (8, 122) . However, antibody testing (Table  3) does not always detect active infection, but is valid for documenting exposure to uncommon viruses such as West Nile virus. Antibody testing is also used for blood-donor screening to identify individuals exposed to human T-lymphotropic virus I and II, hepatitis viruses B and C, HIV-1 and HIV-2.

Rapid diagnosis: the need to identify the pathogen Clinicians would like to determine if an acute infection is of bacterial or viral origin. In contrast to most systemic diseases that display multiple biomarkers, the detection of a single pathogen-specific target can diagnose a disease/infection. Currently, there is no definitive test that distinguishes between a viral and a bacterial infection, other than by testing all of the possible pathogens and/or biomarkers using microarray technology with blood or saliva (20) .

Bacterial infections are ideally treated with narrowrange antibiotics if the bacterial pathogen is identified; however, broad-range antibiotics are typically used when no identification is available. Owing to the emergence of antibiotic-resistant strains of pathogens, antibiograms to determine the susceptibility of pathogens to a variety of antibiotics are increasingly required. These tests are carried out in a clinical microbiology laboratory and it may take hours to days before the appropriate information is available to select the best therapy for treatment of a specific infection.

Acute viral infections are not easily resolved with drugs and require a different approach. The misdiagnosis of a bacterial infection as a viral infection can have fatal consequences, as in the case of bacterial meningitis vs. viral meningitis. In acute infections, when the type of pathogen cannot be established, antibiotics are often prescribed as a precautionary measure. However, high-dose antibiotics in acute bacterial meningitis are toxic and can lead to allergic reactions. Laboratory-based testing to identify the pathogen may require several hours or days to obtain a result. A rapid point-of-care test providing immediate results is desirable and could immediately determine the appropriate treatment. In the case of emergencies, the major issue is the 'sample to assay result time' and saliva or a finger-stick blood test can be utilized for a point-of-care test. In less-acute situations, saliva as a biological matrix for point-of-care diagnosis is well accepted by patients and is preferred when they can choose between finger-stick blood or an oral sample (54) . Moreover, the use of oral samples is ideal for nonhospital settings, such as a local physician's office, a small community health facility, a dental office, first responders and home care.

Studies have reported using oral samples as an alternative to blood or urine samples for the detection of pathogen-specific antigens, antibodies and nucleic acids. In general, the concentration of the target molecules in saliva is lower, but amplification technologies facilitate identification of the viral markers. The use of a saliva sample to replace a lumbar puncture to obtain a sample that unequivocally identifies the pathogen causing acute meningitis would be ideal, but is not yet available. Specific biomolecules derived from any virus circulating in the bloodstream or present in mucosa are likely to be present also in an oral sample. The detection of human antibodies against measles and mumps in oral fluid was first described more than three decades ago (47) and since then several simple platforms for antibody detection in saliva or oral mucosal transudate have been published (33) .

Antibody testing is not widely used for diagnosis of infectious diseases because the presence of antibodies cannot discriminate between a past or current infection as residual antibodies can be present in the 

circulation as a result of a previous immunization. However, a four-fold increase in antibody titer during convalescence may aid in the identification of a particular pathogen but requires an accurate quantitative antibody assay, whereas the existing rapid antibody assays are qualitative, providing a yes/no answer. In contrast, an HIV antibody test can be used to establish HIV-positive status because the infection is not self-cleared and there is no cure or vaccination currently available; therefore, the presence of anti-HIV immunoglobulins can be used as a screening test. However, antibody presence does not correlate with viral load or the ability to transmit the disease; HIV-infected patients on antiviral therapy are antibody positive but may have a viral load below the level of detection. An FDA-approved saliva antibody test is available over-the-counter for home testing (63) . A concern regarding this test is that individuals with suspected exposure to HIV may use it too early postexposure and, as a result, receive a false-negative test result because it takes 6 weeks or longer to mount an antibody response, a time period referred to as the seroconversion window. This situation poses a potential risk as newly infected individuals in the period before seroconversion have extremely high viral loads and are thus highly contagious. There are reports indicating that saliva-based testing has a lower clinical sensitivity than blood-based testing, which may be the case if including HIV-infected individuals receiving highly active antiretroviral therapy (HAART) for an extended period (84) .

In this review, we summarize our unpublished results from two studies demonstrating that the level of antibodies in saliva differ from the level in blood. Although the antibody levels in blood and saliva in HIV-infected individuals differ significantly, all seropositive results were identified when using either blood or saliva as the test fluid. More elaborate laboratory-based testing (e.g. full analysis of blood) is necessary to provide quantitative results because a rapid antibody test only provides a qualitative result. Saliva is preferred as a sample over blood because of higher patient acceptance, issues of safety (no chance of injury caused by needles) and cost (e.g. requirement for a phlebotomist), and is compatible with self-testing. Eventually, oral samples may provide an ideal matrix for diagnosing many other viral infections. Currently, only two oral-based commercial tests for infectious disease are FDA approved for use in the USA: the OraQuick oral HIV test; and the OraRisk human papillomavirus salivary diagnostic test. The OraQuick test (OraSure Technologies, Inc., Bethlehem, PA, USA) is an FDA-approved CLIA waved test using an oral swab specimen. The OraRisk human papillomavirus test (OralDNA labs; Access Genetics, LLC), also FDA approved, utilizes an oral fluid sample sent to a central laboratory for nucleic acid analysis. OraQuick was recently approved as an over-thecounter home-use test, taking 20 min from sample collection to result (a visual line on a test strip). The same platform has been used for development of a commercial oral hepatitis C virus test (66) .

Although antibody assays generally cannot unequivocally diagnose active viral infections, they are valuable tools to track exposure to a pathogen. Antibody screening is useful for epidemiological studies and for monitoring a large population for immunity to common viral infections, whereas the screening of young children for the presence of antibodies against infectious agents thought to be eliminated can be useful to monitor potential re-emergence of a pathogen. Using saliva as a clinical sample for this (large-scale) approach is cost-effective because samples can be collected noninvasively by the participants themselves at home and mailed to a national test laboratory (81, 85) . It is widely accepted that any antibody detectable in blood can also be detected in saliva. However, there are fluctuations and differences in concentration because salivary flow rates vary with circadian rhythm and saliva composition is more variable than that of blood/plasma. Moreover, the antibody isotype differs; salivary glands produce and secrete salivary IgA, whereas IgG and IgM enter the oral cavity through leakage from the bloodstream and gingival crevicular fluid and are present at lower concentrations. Another issue in studies utilizing oral samples is the method of collection; for example, with respect to antibody type, the composition of whole saliva is quite different from the composition of gingival crevicular fluid, which is a transudate that more closely resembles blood. For antibody detection, as a consequence of the high abundancy after seroconversion, the collection method is less critical than is the case when targeting pathogen-derived analytes, such as nucleic acids. In previous studies (22, 67) exploring the development of a modular microfluidic test device for multiplex analysis of saliva samples, a versatile generic antibody assay [ Fig. 1 (22, 29, 31, 32) ] was evaluated using two sets of saliva samples collected using different protocols. Set 1 [WIHS, obtained from the Woman's Interagency HIV Study (10) ] comprised samples, which, upon collection, were immediately stored in a preservative, whereas set 2 (UO1, samples collected during a study funded by National Institute of Dental and Craniofacial Research, NIH grant UO1DE017855) comprised samples, which, upon collection, were clarified using the saliva-collection sponge from the UPlink collector (73) . From both sets, paired serum and saliva samples were tested in parallel to validate saliva results. Figure 2 shows the results obtained with the WIHS (Fig. 2A) and UO1 samples (Fig. 2B) . The assay results are presented as a normalized value, the ratio of the signal measured at the Test line divided by the signal measured at the Flow Control line (27) . Assay cut-off thresholds (the value above which a sample is designated reactive) are determined from the average value obtained with the HIV-negative control samples. The HIV-positive samples uniformly generated a higher assay value than the HIV-negative samples, apparently independently of the saliva-collection protocol. Similar patterns comparing saliva and bloodantibody levels are also observed for other infectious diseases (34) .

Saliva plays a key role in protecting the body from a wide variety of viral infections in addition to its role in controlling the colonization of bacteria in the oral cavity. Many biomolecules in saliva have antiviral activities for specific viruses (74) . Most viral infections occur across mucosal membranes. The mouth and the eye are common sites for viral entry, although viral infections of both the eye and the oral cavity are relatively rare. The mechanism for viral infection control includes many biomolecules, including mucins, antibodies and antiviral proteins that are present in a continuous flow of fluid. It is of interest that many of the same antiviral molecules are present in both saliva and tears and that the hypotonicity of saliva (12) is capable of lysing enveloped viruses.

Responses to an infection involve complex, highly regulated processes. The innate immune system is the first nonspecific defense against both bacteria and viruses. Specific responses include cell-mediated immunity and the adaptive immune system with increased cytokine levels from T-helper cells and the production of anti-pathogen-specific antibodies against pathogen antigens. The secondary response involves the reservoir of specific memory cells, permitting a faster response to a recurring infection by the same pathogen. The presence of specific antibodies and a specific cytokine response from mononuclear blood cells to pathogen-specific antigens can be used as a diagnostic tool (28, 32) , but it does not distinguish between active and latent infections. Confirmation and monitoring of active infections generally requires the detection of pathogen-specific antigens, nucleic acids or cultivation of the pathogen.

As the gateway to the gastrointestinal tract, antiviral activity present in the oral cavity may also prevent viruses from reaching the lower portions of the gastrointestinal tract. Mucins present in saliva, and their production along the entire gastrointestinal tract, serve to trap both bacteria and viruses and prevent colonization. Epithelial surfaces are coated with a group of molecules derived from the innate immune system [e.g. lysozyme, lactoferrin, lactoperoxidase, secretory leukocyte protease inhibitor, gp340 (DMBT1) and defensins], and these are also present in tears and saliva. Considering the vast array of pathogens to which humans are exposed on a daily basis, the level of infection is surprisingly low, indicating that the host-derived protective mechanisms do a remarkable job of bacterial and viral control. Whilst there are many host factors, each pathogen presents a unique mode of infecting and a unique means of host control of infection. Typically, a virus enters a cell by attaching to a specific receptor on the cell surface. In the case of HIV, the virus binds to CD4 and a co-receptor (CCR5 or CXCR4), rabies virus attaches to the neural cell adhesion molecule receptor, whilst herpes simplex virus utilizes a number of cellular receptors, including toll-like receptors. Epstein-Barr virus, responsible for infectious mononucleosis and oral hairy leukoplakia, appears to enter cells by utilizing multiple viral surface proteins and multiple cell receptors, which may increase its oral transmission efficiency. Norovirus, a major cause of gastroenteritis, binds to blood group antigens present on red blood cells and in saliva of secretor-positive individuals. Note that 80% of the population secrete these blood type antigens into saliva.

In the next sections we focus on a number of viral infections detectable in oral fluids, the protective role of saliva and the targets and mechanism involved in the infection pathway (Table 4 ).

Norovirus refers to a family of RNA nonenveloped viruses that are the major cause of nonbacterial gastroenteritis, transmitted by the fecal-oral route (52, 76) following exposure to fecal-contaminated fomites, food or water and possibly also direct person-person contact. Shellfish grown in contaminated waters are 

In contrast to norovirus, rabies virus is usually transmitted via saliva following a bite from an infected animal, which results in encephalitis. It is suggested that spelunkers may become infected after inhalation of aerosols from bat colonies hanging upside down in caves. The disease is most prevalent in areas with endemic dog rabies or infected bats. The virus binds to nicotinic receptors on muscle fibers of a newly infected animal and then migrates via nerves to the brain, where it replicates and spreads via neuronal routes to the salivary gland and ultimately appears in saliva. When the rabies-infected animal bites a human, the spread once again is to the central nervous system and subsequently virus is found in the saliva of the human host. Rabies antigens and antibodies can be detected in saliva of both infected animals and humans, but this is typically late in the infection, making serological detection of little practical value. PCR detection of rabies virus in saliva has been reported (36) . Appropriate pre-exposure (vaccine) and postexposure prophylaxis (rabies immune globulin and vaccine) can be effective with early treatment along with antiviral drugs, otherwise the disease is typically fatal (127) . Massive animal control and pre-exposure vaccines has made rabies-related mortality in the USA relatively rare, with fewer than two deaths per year.

Human papillomaviruses are a family of DNA viruses that infect epithelial cells of the skin and mucosa.

There are over 100 different strains of human papillomavirus and these are able to infect the genital and reproductive tracts, the oral cavity and cause warts predominantly on the hands and feet. In the USA, up to 80% will have a human papillomavirus infection in their lifetime, but most will clear without causing disease. Antibody tests to screen for a potentially active human papillomavirus infection are therefore not considered relevant (38) . Twelve strains of human papillomavirus are considered 'high risk', meaning that they can lead to cancers, primarily cervical and oral cancer. Human papillomavirus strains 16 and 18 are two high-risk strains most frequently associated with cancers or premalignant conditions; ̴ 70% of cervical cancers are attributed to these two strains. However, Beachler et al. (16) , in a study of 404 individuals, found that the most prevalent oral strains were human papillomaviruses 55, 83 and 72. Human papillomavirus strains 16 and 18 are included in national prevention programs, including administration of anti-human papillomavirus vaccines. Oral human papillomavirus infection has a higher prevalence in HIV-infected individuals than uninfected HIV individuals and as a result have a higher risk of developing human papillomavirus-associated cancers, particularly head and neck cancers (15) . Of interest, in a case study of two couples with human papillomavirus-associated tonsillar carcinoma, the human papillomavirus strain 16 was identical in both partners, suggesting the possibility of the infectious nature of oropharyngeal cancer (3) . At present, OralDNA Labs (Access Genetics, LLC) has the only commercially available salivary diagnostic test for human papillomavirus. Oral samples are collected with a swab, placed in transport media and sent to a central laboratory for nucleic acid-based human papillomavirus detection and strain identification. The salivary test, OraRisk human papillomavirus, identifies several human papillomavirus types, with a focus on human papillomavirus-16 and human papillomavirus-18, the types most commonly linked to oral cancers.

Epstein-Barr virus is a member of the Herpesviridae family (DNA viruses) and known to cause disease in humans. It is a lymphocryptovirus targeting B-cells and epithelial cells and is also referred to as human herpesvirus 4. This orally transmitted virus is one of the most common viruses, with a worldwide infection rate of over 90% of the adult population. Although exposure to the virus is high, most primary infections are asymptomatic. However, long-term carriage is associated with epithelial-cell malignancies, including nasopharyngeal carcinoma and oral hairy leukoplakia, and may play a role in many other benign and malignant diseases (56) 

Epstein-Barr virus can spread through sexual contact, blood transfusions and organ transplantation. However, most frequently, transmission is thought to occur through saliva. The virus can survive on objects and surfaces as long as they stay moist and thus can be easily transmitted (e.g. by sharing drinks). There is no vaccine available to prevent infection. Epstein-Barr virus is the cause of the majority of infectious mononucleosis cases (also known as Pfeiffer or the Kissing Disease), common among young adults and teenagers. Infection may cause fatigue and malaise, from which it may take several months to recover (35) . When clinical symptoms indicate mononucleosis-like symptoms, infectious mononucleosis can be confirmed by the presence of atypical lymphocytes and serological tests. In the past, serological diagnostic tests detected the presence of heterophile antibodies (weak antibodies with multispecific activity against poorly defined antigens). Epidemiological studies, using the detection of specific antibodies in saliva to determine population immunity, have been reported (37) . Currently, more sensitive IgG (reflecting past infection) and IgM (reflecting current infection) diagnostics have been developed that reduce the false-negative rate and thus rule out infectious mononucleosis. Previously, the presence of infectious Epstein-Barr virus in saliva was demonstrated by the ability of saliva extracts to transform lymphocytes in culture. Now, nucleic acidbased detection is the most sensitive standard method for detecting infections (61, 110) .

Herpes simplex virus is a double-stranded DNA virus that enters cells through the interaction of viral coat glycoprotein with cellular receptors. The viral capsid is eventually transported to the cell nucleus where its DNA is released into the nucleus and replication is initiated. The linear viral DNA is not integrated in the human genome but remains as an extrachromosomal circular DNA (viral episome). Some oncogenic viruses from the Herpesviridae family, including the Epstein-Barr virus, have been reported to integrate at low frequency into the host chromosome (80) . An association of herpes simplex virus-1 and Epstein-Barr virus with aggressive periodontal disease has been reported, suggesting the possibility that these viruses interact with bacteria linked to periodontal disease (109) .

Herpes simplex virus 1 and herpes simplex virus 2 are two members of the Herpesviridae family. Both are highly contagious and spread easily during periods of shedding. Shedding periods are recognized when individuals have moist blisters on mucous membranes of the lips, mouth and genitals. Cold sores, most frequently on the lips, are a well-recognized sign of herpes simplex virus infection; salivary contact, as well as sharing drinks and food, should then be avoided to prevent transmission of the virus. Herpes simplex virus 2 infection is a common sexually transmitted disease, generally referred to as genital herpes, although both herpes simplex virus 1 and herpes simplex virus 2 have been detected in both oral and genital infections. Herpes simplex virus is a neurotropic virus, capable of infecting nerve cells, and thus can avoid some human immune responses. After active infection and periods of shedding, the virus becomes latent, remaining in neural ganglia. Reactivation of the virus occurs with periods of stress, fatigue and illness, after which the virus is transported through the nerve cell axon to the epithelium where virus replication and shedding occurs.

Herpes simplex virus infections do not self-cure, but remain life-long latent infections that may lead to recurrent infections, although antiviral drugs may reduce the severity of reactivation and decrease the chance of transmission. Herpes infection in neonates can become life threatening as the virus can spread to the central nervous system and cause meningitis or encephalitis. Antiviral medication may be recommended for pregnant woman infected with herpes simplex virus. Currently, no vaccine has been approved for herpes simplex virus, but several studies, mainly focused on a vaccine against genital herpes (herpes simplex virus 2), are ongoing. Most carriers of the virus do not know that they are infected. Reports linking herpes simplex virus 1 infection, and other viruses from the Herpesviridae family, to an increased risk of developing Alzheimer's disease, if confirmed, may change the focus of herpes simplex virus research (19, 75, 78) . Although herpes simplex virus infections are widespread, routine testing for herpes simplex virus is not recommended as the benefits of testing are not clear. As the disease cannot be cured and a vaccine is not available, questions such as 'would it lead to effective reduction of transmission' and 'is testing cost efficient also in relation to false positive test results and confirmatory testing', remain unanswered. Diagnostic laboratory testing, in fact, is only recommended for people who show symptoms of an active infection in order to confirm the diagnosis. Typically, herpes simplex virus 2 infections are considered linked to recurrent genital herpes, but half of the first-episode cases are actually caused by herpes simplex virus 1. Recommended laboratory testing includes a serological test, as well as a virological test (viral culture of the lesion). Viral culture may take up to 10 days and in the future might be replaced by the more accurate nucleic acid testing using PCR.

Several studies describe the detection of anti-herpes simplex virus antibodies and nucleic acid in oral samples. The antibody test is specific to the type of herpes simplex virus and, like nucleic acid testing, can distinguish between herpes simplex virus 1 and herpes simplex virus 2. One of the first reports showing the presence of herpes simplex virus 1-specific IgA antibodies in saliva was published in in 1984 (101) and demonstrated elevated herpes simplex virus 1-specific IgA levels in patients with peptic ulcer. The current dogma is that herpes simplex virus 1 is frequently found in upper gastrointestinal tract ulcers but not in normal gastric and duodenal mucosa, where ulcers are linked to infection with Helicobacter pylori. IgA present in saliva can block the infectivity of herpes simplex virus, as demonstrated in vitro, but the efficiency of viral neutralization in vivo is still unknown. Viable herpes simplex virus can be isolated from saliva, but current methods utilize viral nucleic acid detection, although this is not a quantitative measure of infectious virions. In 1994, Tateishi et al. (117) demonstrated that nucleic acid detection is the most sensitive method for determining herpes simplex virus 1 infection. Rapid antibody tests have been developed for use with blood samples, and modifying the existing rapid tests for detection of antibody in oral fluid would appear to be straightforward. An over-the-counter rapid test would primarily serve to reassure an individual of the absence of herpes simplex virus infection. Whether a rapid test based on the detection of viral antigen or viral nucleic acid in saliva would be useful is a matter of debate because localized sampling of a lesion for diagnosis of genital herpes is available. The situation for viral infections of hepatitis C virus and HIV is clearly different (see below).

The common hepatotropic viruses that cause viral hepatitis are hepatitis viruses A-E. Although their name suggests similarities, the viruses are not related, and they have different properties. Hepatitis D virus, for instance, can only replicate when an individual is already infected with hepatitis B virus. Vaccines are available to prevent infection with hepatitis type A, B and E, although they are not available globally. No vaccine is available for hepatitis C virus, which, according to the US Centers for Disease Control and Prevention, is the most common chronic bloodborne infection in the USA, currently resulting in more mortalities than HIV (69, 70) . In Europe, the prevalence of hepatitis C virus varies from 0.1% in Northern Europe (Finland) to 6% in Eastern Europe (Romania). The core of the current hepatitis C virus epidemic (42) is attributed to injection drug use with contaminated needles. Transmission through sexual contact and from mother-to-child occurs, but at a much lower frequency. In fact, hepatitis C virus transmission follows similar routes as HIV, but the risk of transmission through blood is higher for hepatitis C virus because of its significantly higher viral load.

Like HIV, hepatitis C virus is an RNA virus, but it does not typically integrate into the host DNA. Hepatitis C virus belongs to the flavivirus group of single-stranded enveloped RNA viruses. Replication and mutation rates of hepatitis C virus are much higher than those of HIV, but hepatitis C virus infection is self-cleared in up to 40% of cases. If not cleared, the virus may become latent and activated at a later time. Treatment of acute hepatitis C reduces the risk of chronic infection, and individuals infected with hepatitis C virus are at high risk for developing liver cirrhosis upon infection with hepatitis A virus or hepatitis B virus. Vaccination against hepatitis A virus and hepatitis B virus for individuals with chronic hepatitis C virus infection is therefore advised. Liver cirrhosis caused by a chronic hepatitis C virus infection may lead to liver failure and cancer. Hepatitis C virus infections can be cured, but the existence of multiple genotypes complicates therapeutic approaches and current costs are extremely high, in the order of $100,000 (68) . Currently, six genotypes (1-6), with different geographical distribution, are known; in the USA, genotypes 1-3 are the most common. HIV infection is believed to increase the rate of progression to hepatitis C disease and therefore it is recommended that individuals with a confirmed HIV infection should also be tested for hepatitis C virus. However, the impact of hepatitis C virus infection on HIV disease progression is not significant.

Screening for hepatitis C virus infection is initially performed with a rapid antibody test that delivers results within 20 min (111) . Recently, the OraQuick hepatitis C virus Rapid Antibody Test (67) was approved by the FDA for use with finger-stick blood and it is likely that a saliva test will be made available in the near future. The antibody test does not distinguish between a current and a previous infection; therefore, a confirmatory test is needed if a screening test is positive. Historically, an immunoblot assay was used to confirm infection, but testing for hepatitis C virus RNA is currently the method of choice.

A strong correlation between serum and salivary antibody levels against hepatitis C virus infections have been reported since 1986 (4). One of the first studies successfully demonstrating anti-hepatitis C virus antibodies in saliva was published in 1992 (118) . Since then, rapid testing using saliva has evolved (131) to a rapid test that requires only 20 min from 'sample to result' (66) . The latter, low-complexity, user-friendly test was built on the same platform as the OraQuick Advance HIV1/2 Rapid Test. Although the hepatitis C virus test device may become FDA approved to determine the presence of antibodies in oral samples in the future, a confirmatory test to determine an active infection will still be needed. As hepatitis C virus transmission requires blood-blood contact, it was proposed that a saliva-based diagnostic might be safer than blood for testing. Infectious hepatitis C virus in saliva has been observed, but generally only for individuals with periodontal disease or gingivitis and a serum viral load higher than 10 6 virions/ml. Infection through salivary contact is unlikely, but cannot be fully excluded.

HIV contains two separate, but identical, strands of (+) RNA, which, upon infection, are transcribed into DNA that enters the nucleus and integrates into the human genome. Once this occurs, the infected cell produces viral particles that can infect new cells. The virus targets CD4 + T-helper cells and other cells from the immune system and thereby affects cell-mediated immunity, making the individual progressively more vulnerable to other opportunistic infections and AIDS-related cancers. Upon integration of the viral DNA into the human genome, the infection cannot be cleared and remains life-long in still-unknown reservoirs. For patient survival and blocking progression to full-blown AIDS, compliance with a strict drug regime needs to be followed to suppress virus production and the continuous infection of new CD4 cells.

Early HIV infection is not easily diagnosed as the symptoms resemble influenza. Individuals aware of having been at risk for HIV infection may request an HIV test; however, an antibody test can demonstrate HIV infection only after seroconversion, which can take up to 6 weeks. Recent infections require another approach. The best way to demonstrate early infection is by nucleic acid amplification.

Depending on the risk factor, postexposure prophylaxis in health-care workers or individuals suspecting exposure to HIV (e.g. unprotected sexual contact or use of a contaminated needle) can be considered. In the case of health-care workers, after postexposure prophylaxis, individuals will have to remain alert for several weeks for potential signs of HIV infection. Pre-exposure prophylaxis with antiretroviral drugs has been demonstrated to reduce the risk of infection for individuals involved in high-risk behaviors (www.cdc.gov/hiv/prevention/research/prep/). In many cases, HIV infection will initially go unnoticed until an individual has a medical consultation related to a secondary opportunistic infection. Usually at that point the individual is past the HIV seroconversion window and infection can be identified with a rapid antibody screening test. As HIV infection is not curable, it is highly likely that a person with antibodies against HIV is infected, but a confirmatory test to validate the antibody test result is required to exclude a false-positive result. For the patient this waiting period, up to a week or more, to get the final test result can be difficult psychologically. For this reason, point-of-care devices that can be used to diagnose and validate HIV infection within 1 or 2 h are important. If the device is also able to determine an accurate viral load, counseling could be included concomitantly with the immediate start of appropriate antiretroviral therapy. This would also reduce the number of individuals required to return to the clinic to receive their confirmatory test result and may thus decrease transmission of the virus. Fourth-generation immunoassays that detect the p24 antigen and anti-HIV immunoglobulins have been developed but are not readily available for the most point-of-care settings (57, 128) . The combination of nucleic acid and antibody detection is a better option as a result of the availability of nucleic acid-amplification methods that achieve the desired sensitivity (22) and also allow detection of an early infection (before seroconversion). The ultimate (point-of-care) device allows detection of anti-HIV immunoglobulins, viral antigen (e.g. soluble p24), viral RNA, as well as pro-viral DNA (34) . This type of device provides both screening and confirmation of infection within the seroconversion window as the presence of viral RNA could be confirmed either by the presence of viral antigens or by proviral DNA. Note that detection of anti-HIV immunoglobulins is the simplest method to screen for an HIV infection. However, neonates from HIV-infected mothers carry maternal anti-HIV immunoglobulins for up to 1 year whilst not being infected (25) .

The three main transmission routes of HIV infection are unprotected sexual intercourse, the use of contaminated needles and transmission from mother to child during pregnancy, birth and breastfeeding. The role of saliva in both the diagnosis and inhibition of HIV has been a widely discussed topic (for reviews see Page-Shafer et al. and Shiboski et al. (89, 103) ). The presence of viable HIV particles in saliva is controversial (11, 105) . Detection of HIV nucleic acids in saliva has been demonstrated, but it is not clear whether the viral RNA detected is derived from viable viral particles or instead represents free nucleic acid fragments. In general, the viral loads in saliva are lower than those in the corresponding blood sample (46) . Occasionally, high secretors of HIV have been reported, perhaps indicating the presence of reservoirs for HIV in salivary glands or oropharyngeal tissue. Infected lymphocytes from various oral sources are a possible source of HIV in viral hypersecretors (106) . It is important to recognize the presence of reservoirs as a potential source of transmission. Thousand-fold higher viral RNA levels have been reported in tonsil biopsies than in the corresponding blood samples (43) . Even more remarkable is the detection of 10 7 HIV copies per ml in parotid cyst aspirates in individuals with undetectable blood viremia (120) . Although the presence of reservoirs is acknowledged and the existence of HIV in epithelial cells of the buccal mucosa has been demonstrated (40, 79) , saliva is not regarded as a relevant transmission route (88) . Saliva lyses HIV particles in vitro because of its hypotonicity (11) and many salivary proteins have been demonstrated to inhibit HIV infectivity in vitro, including lysozyme, cysteine-rich defensins, lactoferrin, secretory leukocyte protease inhibitor and salivary agglutinin (gp340, DMBT1). In the oral cavity, soluble gp340 is thought to inactivate HIV by a mechanism involving binding to a HIV glycoprotein (gp120) exposed on the HIV envelope (74, 83) .

The oral cavity is a major site for infection and transmission of viruses (108) . The innate immune system present in the mouth can prevent some infections (e.g. HIV), whereas other viruses, including rabies, herpes simplex virus and Epstein-Barr virus, can infect and be transmitted orally. Of particular importance is that defensive antibodies to most bacterial and viral pathogens can be detected using saliva or a swab of the oral mucosa. The frequency of oral-based testing for viral and bacterial diseases is increasing as more commercial entities become involved and new products are being developed. The major advantages of oral-based testing are cost, patient acceptance, equivalence to blood testing and the possibility of home testing. Whether increased testing for viral infections should be recommended depends on several factors, of which cost is extremely important. Inexpensive and rapid saliva diagnostics can be used in a dental office to provide screening tests for many viral diseases, including HIV, hepatitis C virus and influenzain fact, all situations where a blood-based antibody test is performed. Moreover, when oral symptoms suggest, or when requested by the patient, the dentist could conveniently initiate viral nucleic acid-based testing by collection of the appropriate oral sample to send to a central laboratory for further analysis and inform the patient's physician for follow up. Alternatively, the rapid oral antibody test could be performed in the dentist's office and, if the screening result is reactive, the patient can be referred immediately to a clinic for a confirmatory test.

Scientific literature indicates that several commercial assays may be suitable for use with oral samples. Several research laboratories are developing oral fluid-based tests for infectious diseases and several noninfectious systemic diseases. Special attention is required for assays that can be performed at home by individuals themselves when they involves diseases with potentially great social impact (e.g. HIV) as the patient may not always act appropriately upon receiving the test result. As large numbers of individuals visit a dentist annually as their only health professional (114) , screening for viral infections in the dental office followed by referral to a physician could have a major impact on controlling the transmission and symptoms of infectious diseases. selecting and shipping the paired saliva and serum samples from the WIHS cohort collection; The Bronx/ Manhattan WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004) and co-funded by the National Cancer Institute. Cheryl Barber (NYU) is acknowledged for organizing the UO1 collection bank. Collection of the UO1 sample bank, development and validation and of the UCP-LF antibody assay was performed, in part, with financial support from the US National Institutes of Health grants UO1DE017855 and R01AI094599.

Exposure to multiple subgenotypes of hepatitis A virus during an outbreak using matched serum and saliva specimens

An evaluation of dried blood spots and oral swabs as alternative specimens for the diagnosis of dengue and screening for past dengue virus exposure

Concurrent human papillomavirus-associated tonsillar carcinoma in 2 couples

Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection

Saliva as a tool in the detection of hepatitis B surface antigen in patients

Detection of HIV-1 in saliva: implications for case-identification, clinical monitoring and surveillance for drug resistance

Tobacco mosaic virus in cigarettes and saliva of smokers

Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies

Hepatitis B virus transmission in pre-adolescent schoolchildren in four multi-ethnic areas of England

The women's interagency HIV study WIHS collaborative study group

Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes

Oral transmission of human immunodeficiency virus by infected seminal fluid and milk: a novel mechanism

Recovery of infectious HIV-1 from whole saliva

Assessment of the risk of Ebola virus transmission from bodily fluids and fomites

Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals

Natural history of anal vs oral HPV infection in HIV-infected men and women

Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns

Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly

Herpes virus in Alzheimer's disease: relation to progression of the disease

Evaluation of biological sample preparation for immunosignature-based diagnostics

Human papilloma virus prevalence in a multiethnic screening population

Development of a generic microfluidic device for simultaneous detection of antibodies and nucleic acids in oral fluids

Effect of acute Plasmodium falciparum malaria on reactivation and shedding of the eight human herpes viruses

Evaluation of high-throughput sequencing for identifying known and unknown viruses in biological samples

Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States

Correlation of nonspecific antiviral activity with the ability to isolate infectious HIV-1 from saliva

Use of up-converting phosphor reporters in lateral-flow assays to detect specific nucleic acid sequences: a rapid, sensitive DNA test to identify human papillomavirus type 16 infection

Lateral flow assay for simultaneous detection of cellular-and humoral immune responses

A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study

Infrared up-converting phosphors for bioassays

Tools for diagnosis, monitoring and screening of Schistosoma infections utilizing lateral-flow based assays and upconverting phophor labels

Rapid assay format for multiplex detection of humoral immune responses to infectious disease pathogens (HIV, HCV, and TB)

Chapter 13 -Point-of-Care diagnostics for infectious diseases

Detecting viruses by using salivary diagnostics

Biology and disease associations of Epstein-Barr virus

Intravitam diagnosis of human rabies by PCR using saliva and cerebrospinal fluid

Epidemiology of Epstein-Barr virus infection in pre-adolescent children: application of a new salivary method in Edinburgh Scotland

Understanding HPV tests and their appropriate applications

Salivary shedding of Epstein-Barr virus and cytomegalovirus in people infected or not by human immunodeficiency virus 1

Short communication: HIV type 1 escapes inactivation by saliva via rapid escape into oral epithelial cells

Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus

The changing epidemiology of hepatitis C virus infection in Europe

Outpatient biopsies of the palatine tonsil: access to lymphoid tissue for assessment of human immunodeficiency virus RNA titers

Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo

Microfluidic designs and techniques using lab-on-a-chip devices for pathogen detection for point-of-care diagnostics

Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses

Radioimmunoassay for the detection of virus-specific IgA antibodies in saliva

Assessment of salivary human herpesvirus-6 and immunoglobulin A Levels in nurses working shifts

Comparison of Simplexa HSV 1 & 2 PCR with culture, immunofluorescence, and laboratory-developed TaqMan PCR for detection of herpes simplex virus in swab specimens

Andreoletti L. Virological diagnosis and management of two cases of congenital measles

Secretory immunoglobulin A in saliva of women with oral and genital HPV infection

Norovirus gastroenteritis

Prospective study of enteroviral infections and development of beta-cell autoimmunity. Diabetes autoimmunity study in the young (DAISY)

Patients' attitudes toward screening for medical conditions in a dental setting

Development of a multiplex microsphere immunoassay for the quantitation of salivary antibody responses to selected waterborne pathogens

Laboratory assays for Epstein-Barr virus-related disease

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay

Frequent shedding of human herpesvirus 6 in saliva

Measles vaccination coverage estimates from surveys, clinic records, and immune markers in oral fluid and blood: a population-based cross-sectional study

The role of RT-PCR assay of oral fluid for diagnosis and surveillance of measles, mumps and rubella

Higher prevalence of Epstein-Barr virus DNA in deeper periodontal pockets of chronic periodontitis in Japanese patients

Detection of Hiv-P24 antigen in body-fluids by immunotrapping on Staphylococcus aureus (Cowan-1) bacteria. Gold immunolabeling and backscattered electron analysis in a scanning electron-microscope

Home testing for HIV: hopefully, a step forward

Lack of correlation between virus detection and serologic tests for diagnosis of active cytomegalovirus-infection in patients with aids

Recovery of culturable tobacco mosaic virus from sputum and thoracentesis fluids obtained from cigarette smokers with a history of pulmonary disease

Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid

Evaluation of a rapid, point-ofcare test device for the diagnosis of hepatitis C infection

Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas

Causes of death and characteristics of decedents with viral hepatitis, United States

The increasing burden of mortality from viral hepatitis in the United States between

Microfluidic sample preparation for diagnostic cytopathology

Rapid diagnosis of rabies in humans and animals by a dot blot enzyme immunoassay

Point detection of pathogens in oral samples

The mouth: a gateway or a trap for HIV?

Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer's disease

Norovirus as a foodborne disease hazard

Salivary production of IgA and IgG to human herpes virus 8 latent and lytic antigens by patients in whom Kaposi's sarcoma has regressed

Emerging roles of pathogens in Alzheimer disease

HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation

Herpesviruses and chromosomal integration

A novel method of oral fluid collection to monitor immunity to common viral infections

Ante mortem diagnosis of human rabies using saliva samples: comparison of real time and conventional RT-PCR techniques

Human submandibular saliva inhibits human immunodeficiency virus type 1 infection by displacing envelope glycoprotein gp120 from the virus

Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy

Oral fluid collection by post for viral antibody testing

HIV excretion patterns and specific antibody responses in body fluids

Influenza vaccine effectiveness in the community and the household

Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men

C2) Saliva, breast milk, and mucosal fluids in HIV transmission

Genetic analysis of norovirus GII.4 variants circulating in Korea

Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula

Performance of rapid point-ofcare and laboratory tests for acute and established HIV infection in San Francisco

Detection of dengue virus in saliva and urine by real time RT-PCR

Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome

Causes of morbilliform rash in a highly immunised English population

Evaluation of different continuous cell lines in the isolation of mumps virus by the shell vial method from clinical samples

Evaluation of an ultrasensitive p24 antigen assay as a potential alternative to human immunodeficiency virus type 1 RNA viral load assay in resource-limited settings

Shedding of polyomavirus in the saliva of immunocompetent individuals

Use of throat swab or saliva specimens for detection of respiratory viruses in children

Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York city in 2009

IgA antibodies to herpes simplex virus type 1 in duodenal juice and saliva from patients with peptic ulcer and non-ulcer controls

All known human rhinovirus species are present in sputum specimens of military recruits during respiratory infection

Overview of the oral HIV/AIDS research alliance program

Early childhood stress is associated with elevated antibody levels to herpes simplex virus type 1

Endogenous salivary inhibitors of human immunodeficiency virus

Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva

Six fatal cases of classical rabies virus without biting incidents

Oral viral infections of adults

Human viruses in periodontitis

Epstein-Barr virus in oral diseases

Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus

Detection of hepatitis C virus RNA in saliva of patients with active infection not associated with periodontal or liver disease severity

Rapid detection of human torque teno viruses using high-resolution melting analysis

Identifying unaddressed systemic health conditions at dental visits: patients who visited dental practices but not general health care providers in 2008

A case of acute hepatitis B related to previous gynecological surgery in Japan

Development and evaluation of Varicella zoster virus ELISA for oral fluid suitable for epidemiological studies

Detection of herpes simplex virus (HSV) in the saliva from 1,000 oral surgery outpatients by the polymerase chain reaction (PCR) and virus isolation

Clinical evaluation of oral fluid samples for diagnosis of viral hepatitis

Could oral fluid be used to evaluate antihepatitis A virus status in individuals living in difficult-toaccess areas

The benign cystic lymphoepithelial lesion of the parotid gland is a viral reservoir in HIV type 1-infected patients

Blazevic V. Comparison of human saliva and synthetic histoblood group antigens usage as ligands in norovirus-like particle binding and blocking assays

Kinetics of antibodies in sera, saliva, and urine samples from adult patients with primary or secondary dengue 3 virus infections

Virology of infantile chronic recurrent parotitis in Santiago de Chile

Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection

A comparison of oral fluid collection devices for use in the surveillance of virus diseases in children

Development and evaluation of a rapid immunochromatographic test for mumps-specific IgM in oral fluid specimens and use as a matrix for preserving viral nucleic acid for RT-PCR

Review of human rabies prophylaxis and treatment

Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays

Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children

Cytomegalovirus infections among African-Americans

Detection of HCV salivary antibodies by a simple and rapid test

Virus activation and immune function during intense training in rugby football players

Use of saliva for early dengue diagnosis

Samples from one cohort used in this study were collected by the Women's Interagency HIV Study (WIHS) and its associated Collaborative Study Groups. Kathryn Anastos is acknowledged for providing,